Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BergaMet North America is a nutraceutical company that specializes in the development and distribution of high-potency citrus bergamot supplements. The company's products are centered around the patented Bergamot Polyphenolic Fraction (BPF), which is clinically studied for its ability to support healthy cholesterol levels, blood glucose metabolism, and cardiovascular health. BergaMet works closely with medical professionals and researchers to provide evidence-based natural alternatives for managing metabolic syndrome and lipid profiles. Their product line includes specialized formulations such as BergaMet Pro+ and BergaMet Mega+5, which combine bergamot with other synergistic ingredients like alpha-cyclodextrin and olive leaf extract. The company serves as the primary North American distributor for these specific Italian-sourced bergamot extracts.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BergametNA.